At a glance
- Originator SSP Co
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 04 Aug 1998 Discontinued-Preclinical for Bacterial infections in Japan (Unknown route)
- 13 May 1996 Preclinical development for Bacterial infections in Japan (Unknown route)